Results 11 to 20 of about 2,875 (114)

Comparison of safety of lecanemab and donanemab: a real-world disproportionality analysis using the FDA adverse event reporting system [PDF]

Frontiers in Pharmacology
BackgroundLecanemab and donanemab are anti-amyloid-β (Aβ) monoclonal antibodies recently approved for the treatment of Alzheimer’s disease (AD). Although both agents have demonstrated therapeutic potential, their post-marketing adverse event reporting ...
Xiuping Feng, Xiuping Feng, Shangqing Bi, Shangqing Bi, Chaoqiong Shi, Chaoqiong Shi, Qingqing Chang, Qingqing Chang, Jiaming Zhang, Jiaming Zhang, Yiyang Zhuang, Yiyang Zhuang   +11 more
doaj   +2 more sources

Targeting Amyloid Pathology in Early Alzheimer’s: The Promise of Donanemab-Azbt

Pharmacy (Basel, Switzerland)
Objective: The purpose of this review is to examine the potential role of donanemab-azbt in the treatment and management of early-stage Alzheimer’s disease (AD), with a focus on its efficacy, safety, and clinical relevance based on data from key clinical
Nadia Khartabil
exaly   +3 more sources

Real-world anti-amyloid therapy beyond traditional symptomatic populations: a longitudinal case series [PDF]

Frontiers in Psychiatry
IntroductionAnti-amyloid monoclonal antibodies are approved as disease-modifying therapies for early Alzheimer’s disease (AD), but real-world evidence remains limited, particularly among individuals treated during preclinical or minimally symptomatic ...
Jayoung Han, Yuan Fang, Darlingtina Esiaka, Olufunmilola Abraham   +3 more
doaj   +2 more sources

Re-Evaluation of the Efficacy and Safety of Anti-Aβ Monoclonal Antibodies (Lecanemab/Donanemab) in the Treatment of Early Alzheimer’s Disease

Frontiers in Pharmacology
ObjectiveTo systematically evaluate the efficacy and safety of anti-Aβ monoclonal antibodies (Lecanemab/Donanemab) in the treatment of early Alzheimer’s disease (AD) and to provide evidence for rational clinical use.MethodsWe searched databases including
Haoyang Wang, Junying Pan, Mingming Zhang, Zengde Tan   +3 more
exaly   +3 more sources

FDA Approval of Donanemab‐azbt: A New Dawn in Alzheimer's Disease Treatment [PDF]

Health Science Reports
Background Alzheimer's disease (AD) is a neurodegenerative condition marked by the accumulation of beta‐amyloid plaques and neurofibrillary tangles, leading to neuronal death and cognitive decline.
Rumaisa Riaz, Marrium Fatima, Sadia Ramzan, Diya Rathi, Filzah Fatima, Maha Farooq, Ayesha Shaukat, Nawal Khaliq, Aymar Akilimali   +8 more
doaj   +2 more sources

The Centiloid Scale in Amyloid PET Imaging: Current Role in Alzheimer’s Disease Diagnosis, Treatment Planning, and Monitoring During Anti-Amyloid Therapy: A Clinical Perspective [PDF]

Diagnostics
Amyloid positron emission tomography (PET) has become a critical tool in the diagnosis and treatment of Alzheimer’s disease (AD). The Centiloid (CL) scale, a tracer/scanner-independent, standardized quantification unit introduced in 2015, transforms ...
Houman Sotoudeh, Mohammadreza Alizadeh
doaj   +2 more sources

Pharmacological and Clinical Heterogeneity of Anti-Amyloid Monoclonal Antibodies in Early Alzheimer’s Disease: A Systematic Review and Meta-Analysis of Randomized Trials [PDF]

Medical Sciences
Background: Anti-amyloid monoclonal antibodies represent the first disease-modifying therapeutic strategy targeting amyloid-β pathology in early Alzheimer’s disease (AD).
Albert Vamanu, Alexandra Mastaleru, Thomas Gabriel Schreiner, Gabriela Popescu, Adina Maria Roceanu, Andrei Ionut Cucu, Alexandru Patrascu, Georgiana-Anca Vulpoi, Robert-Valentin Bilcu, Romica Sebastian Cozma, Raluca Olariu, Cătălina Elena Bistriceanu, Roxana Covali, Dan Iulian Cuciureanu, Alin Ciubotaru   +14 more
doaj   +2 more sources

In-vitro interaction studies between the amyloid PET tracer florbetaben and the amyloid-beta targeting antibodies lecanemab and donanemab on AD brain samples reveal no interferences [PDF]

Alzheimer’s Research & Therapy
Background Amyloid PET imaging enables the in vivo visualization and quantification of amyloid-beta deposits in the brain. In research and clinical settings, it is further used to monitor amyloid-beta burden as well as the biological response to disease ...
Andre Mueller, Aleksandar Jovalekic, Marianne Chapleau, Julius Seidel, Maria Ritter, Eva-Maria Bickel, Nadine Kiessling, Emer MacSweeney, Andrew W. Stephens, Norman Koglin   +9 more
doaj   +2 more sources

Real‐world determinants of time to initiation of anti‐amyloid treatments: comparative data from private and academic practice settings [PDF]

Alzheimer’s & Dementia: Diagnosis, Assessment & Disease Monitoring
INTRODUCTION Earlier anti‐amyloid therapy (AAT) initiation results in improved clinical outcomes in Alzheimer's disease (AD). We sought to identify demographic, clinical, and disease‐related factors impacting door‐to‐treatment times (DTTs).
Varun Mehta, Divya Singh, Jordyn Kelman, Saanvi Nimma, Helen Lutz, Andrea Schnee, David Weisman, Michael H. Rosenbloom   +7 more
doaj   +2 more sources

Correction to "Translational Medicine in Alzheimer's Disease: The Journey of Donanemab From Discovery to Clinical Application". [PDF]

Chronic Dis Transl Med
Chronic Diseases and Translational Medicine, EarlyView.
europepmc   +2 more sources